See more : CKD Bio Corp. (063160.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Olympus Corporation (OCPNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Olympus Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Accelerate Acquisition Corp. (AAQCW) Income Statement Analysis – Financial Results
- OKYO Pharma Limited (OKYO.L) Income Statement Analysis – Financial Results
- Orthofix Medical Inc. (OFIX) Income Statement Analysis – Financial Results
- Century Communities, Inc. (CCS) Income Statement Analysis – Financial Results
- Churchill Capital Corp IX Unit (CCIXU) Income Statement Analysis – Financial Results
Olympus Corporation (OCPNF)
About Olympus Corporation
Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through four segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, endoscopy system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials and orthopedic equipment. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 936.21B | 881.92B | 750.12B | 730.54B | 755.23B | 793.86B | 786.50B | 740.56B | 804.58B | 764.67B | 713.29B | 743.85B | 848.55B | 847.11B | 883.09B | 980.80B | 1,128.88B | 1,061.79B | 978.13B | 813.54B | 633.62B | 564.34B | 528.42B | 466.70B | 428.65B |
| Cost of Revenue | 311.09B | 319.23B | 274.13B | 302.56B | 310.67B | 314.16B | 305.39B | 292.99B | 270.10B | 274.82B | 272.83B | 365.65B | 464.74B | 459.42B | 474.84B | 519.58B | 619.40B | 611.50B | 619.90B | 516.47B | 335.05B | 293.53B | 308.64B | 271.44B | 0.00 |
| Gross Profit | 625.12B | 562.70B | 475.99B | 427.99B | 444.56B | 479.70B | 481.11B | 447.57B | 534.48B | 489.85B | 440.46B | 378.20B | 383.81B | 387.69B | 408.24B | 461.22B | 509.48B | 450.28B | 358.23B | 297.07B | 298.57B | 270.81B | 219.78B | 195.26B | 428.65B |
| Gross Profit Ratio | 66.77% | 63.80% | 63.46% | 58.58% | 58.86% | 60.43% | 61.17% | 60.44% | 66.43% | 64.06% | 61.75% | 50.84% | 45.23% | 45.77% | 46.23% | 47.03% | 45.13% | 42.41% | 36.62% | 36.52% | 47.12% | 47.99% | 41.59% | 41.84% | 100.00% |
| Research & Development | 0.00 | 76.87B | 85.30B | 23.20B | 91.60B | 94.00B | 89.50B | 79.18B | 81.42B | 74.10B | 66.80B | 63.38B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 473.23B | 420.55B | 357.51B | 357.03B | 381.17B | 437.51B | 426.60B | 397.70B | 430.77B | 398.89B | 367.01B | 343.12B | 348.29B | 0.00 | 0.00 | 0.00 | 396.86B | 351.55B | 295.71B | 273.92B | 235.57B | 208.47B | 177.50B | 159.76B | 0.00 |
| Selling & Marketing | 0.00 | -113.84B | -116.18B | -57.08B | -129.81B | -123.98B | -119.27B | -30.92B | -82.17B | 42.91B | 41.89B | 39.95B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 473.23B | 306.70B | 241.33B | 299.95B | 251.36B | 313.53B | 307.33B | 366.78B | 348.60B | 398.89B | 367.01B | 343.12B | 348.29B | 0.00 | 0.00 | 0.00 | 396.86B | 351.55B | 295.71B | 273.92B | 235.57B | 208.47B | 177.50B | 159.76B | 0.00 |
| Other Expenses | 108.29B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 79.18B | -1.66B | -7.80B | -9.51B | -10.10B | -7.66B | -6.50B | -5.42B | -5.73B | -6.53B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 581.53B | 383.57B | 326.63B | 323.15B | 342.96B | 407.53B | 396.83B | 366.78B | 430.02B | 398.89B | 367.01B | 343.12B | 348.29B | 349.31B | 348.10B | 426.64B | 396.86B | 351.55B | 295.71B | 273.92B | 235.57B | 208.47B | 177.50B | 159.76B | 0.00 |
| Cost & Expenses | 892.61B | 702.80B | 600.77B | 625.71B | 653.63B | 721.69B | 702.22B | 659.77B | 700.11B | 673.71B | 639.84B | 708.77B | 813.03B | 808.73B | 822.94B | 946.22B | 1,016.25B | 963.06B | 915.60B | 790.39B | 570.63B | 502.00B | 486.13B | 431.21B | 0.00 |
| Interest Income | 2.56B | 3.70B | 1.01B | 817.00M | 1.28B | 1.30B | 1.13B | 774.00M | 1.09B | 732.00M | 1.07B | 1.05B | 931.00M | 894.00M | 1.12B | 2.42B | 3.20B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 10.31B | 6.03B | 5.14B | 4.27B | 4.41B | 5.03B | 7.05B | 8.58B | 7.89B | 8.92B | 11.47B | 13.94B | 14.03B | 12.74B | 12.41B | 16.19B | 13.91B | 11.26B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 65.94B | 66.74B | 64.62B | 59.94B | 68.31B | 58.67B | 52.91B | 54.29B | 49.78B | 50.64B | 46.31B | 43.58B | 46.07B | 46.44B | 58.27B | 146.26B | 45.60B | 38.27B | 32.70B | 29.76B | 24.25B | 16.86B | 23.70B | 18.25B | 0.00 |
| EBITDA | 112.10B | 238.83B | 233.17B | 160.81B | 158.29B | 119.18B | 132.63B | 135.08B | 154.24B | 142.35B | 119.75B | 76.67B | 50.60B | 79.12B | 115.80B | 180.85B | 154.12B | 136.34B | 95.22B | 52.91B | 87.25B | 79.20B | 65.98B | 53.74B | 428.65B |
| EBITDA Ratio | 11.97% | 27.88% | 28.53% | 22.55% | 22.50% | 16.48% | 17.44% | 18.24% | 19.17% | 17.21% | 15.24% | 9.20% | 8.81% | 9.73% | 13.11% | 18.44% | 13.52% | 12.84% | 11.03% | 7.84% | 13.76% | 14.95% | 13.02% | 12.55% | 100.00% |
| Operating Income | 43.60B | 179.13B | 149.36B | 104.84B | 101.60B | 72.17B | 84.28B | 80.79B | 104.46B | 90.96B | 73.45B | 35.08B | 35.52B | 38.38B | 60.15B | 34.59B | 112.62B | 98.73B | 62.52B | 23.15B | 63.00B | 62.35B | 42.28B | 35.50B | 428.65B |
| Operating Income Ratio | 4.66% | 20.31% | 19.91% | 14.35% | 13.45% | 9.09% | 10.72% | 10.91% | 12.98% | 11.90% | 10.30% | 4.72% | 4.19% | 4.53% | 6.81% | 3.53% | 9.98% | 9.30% | 6.39% | 2.85% | 9.94% | 11.05% | 8.00% | 7.61% | 100.00% |
| Total Other Income/Expenses | -7.74B | -4.81B | -7.66B | -5.18B | -14.99B | -52.05B | -7.62B | -14.01B | -33.66B | -82.03B | -57.02B | -15.94B | -45.01B | -18.44B | 26.06B | -125.89B | -18.01B | -25.15B | -19.34B | -17.18B | -2.80B | -19.35B | -21.84B | -13.88B | -428.65B |
| Income Before Tax | 35.85B | 181.80B | 140.21B | 76.22B | 86.13B | 20.12B | 76.67B | 62.48B | 70.80B | 8.93B | 16.43B | 19.14B | -9.50B | 19.94B | 86.20B | -91.30B | 94.61B | 73.58B | 43.19B | 5.97B | 60.20B | 42.99B | 20.44B | 21.61B | 0.00 |
| Income Before Tax Ratio | 3.83% | 20.61% | 18.69% | 10.43% | 11.40% | 2.53% | 9.75% | 8.44% | 8.80% | 1.17% | 2.30% | 2.57% | -1.12% | 2.35% | 9.76% | -9.31% | 8.38% | 6.93% | 4.42% | 0.73% | 9.50% | 7.62% | 3.87% | 4.63% | 0.00% |
| Income Tax Expense | 8.88B | 44.30B | 31.07B | 11.14B | 26.04B | 12.07B | 19.57B | 19.67B | 8.15B | 17.81B | 2.80B | 10.90B | 39.28B | 15.63B | 38.27B | 25.87B | 36.76B | 26.08B | 14.83B | 17.80B | 26.64B | 18.65B | 10.16B | 9.83B | -1.86B |
| Net Income | 242.57B | 143.43B | 115.74B | 57.71B | 80.29B | 8.15B | 57.06B | 42.78B | 62.59B | -8.74B | 13.63B | 8.02B | -48.99B | 3.87B | 47.76B | -114.81B | 57.97B | 47.80B | 28.56B | -11.83B | 33.56B | 24.35B | 10.28B | 11.79B | 1.86B |
| Net Income Ratio | 25.91% | 16.26% | 15.43% | 7.90% | 10.63% | 1.03% | 7.26% | 5.78% | 7.78% | -1.14% | 1.91% | 1.08% | -5.77% | 0.46% | 5.41% | -11.71% | 5.14% | 4.50% | 2.92% | -1.45% | 5.30% | 4.31% | 1.95% | 2.53% | 0.43% |
| EPS | 2.40 | 113.22 | 90.22 | 44.89 | 61.18 | 5.97 | 41.71 | 31.25 | 45.73 | -6.38 | 10.26 | 7.24 | -45.88 | 3.60 | 44.31 | -107.21 | 53.62 | 44.20 | 26.50 | -11.25 | 31.74 | 22.97 | 9.72 | 11.14 | 1.76 |
| EPS Diluted | 21.88 | 113.08 | 90.17 | 44.87 | 61.15 | 5.96 | 41.69 | 31.24 | 45.71 | -6.38 | 10.26 | 7.24 | -45.88 | 3.60 | 44.31 | -106.99 | 53.61 | 44.20 | 26.50 | -11.25 | 31.74 | 22.97 | 9.72 | 11.14 | 1.76 |
| Weighted Avg Shares Out | 11.09B | 1.27B | 1.28B | 1.29B | 1.31B | 1.37B | 1.37B | 1.37B | 1.37B | 1.37B | 1.33B | 1.11B | 1.07B | 1.07B | 1.08B | 1.07B | 1.08B | 1.08B | 1.08B | 1.05B | 1.06B | 1.06B | 1.06B | 1.06B | 1.06B |
| Weighted Avg Shares Out (Dil) | 1.22B | 1.27B | 1.28B | 1.29B | 1.31B | 1.37B | 1.37B | 1.37B | 1.37B | 1.37B | 1.33B | 1.11B | 1.07B | 1.07B | 1.08B | 1.07B | 1.08B | 1.08B | 1.08B | 1.05B | 1.06B | 1.06B | 1.06B | 1.06B | 1.06B |
Olympus Corporation (OLYMY) Q2 2025 Earnings Call Transcript
Olympus Corporation (OTCPK:OLYMY) Q2 2025 Earnings Conference Call November 8, 2024 1:00 AM ET Company Participants Yasuo Takeuchi - Director, Representative Executive Officer, Executive Chairperson and ESG Officer Tatsuya Izumi - Executive Officer and Chief Financial Officer Frank Drewalowski -...
Olympus Corporation (OLYMY) Q1 2025 Earnings Call Transcript
Olympus Corporation (OTCPK:OLYMY) Q1 2025 Earnings Conference Call August 7, 2024 2:00 AM ET Company Participants Stefan Kaufmann - Executive President, CEO & Director Tatsuya Izumi - Executive Officer & CFO Gabriela Kaynor - Executive Officer, Chief Strategy Officer Conference...
Olympus Corporation (OLYMY) Q4 2024 Earnings Call Transcript
Olympus Corporation (OTCPK:OLYMY) Q4 2024 Earnings Call Transcript May 10, 2024 2:00 AM ET Company Participants Stefan Kaufmann - President & Chief Executive Officer Tatsuya Izumi - Chief Financial Officer Frank Drewalowski - Executive Officer and Endoscopic Solutions Division Head...
Olympus Corporation (OLYMY) Q3 2024 Earnings Call Transcript
Olympus Corporation (OLYMY) Q3 2024 Earnings Call Transcript
Olympus Corporation (OCPNF) Q2 2024 Earnings Call Transcript
Olympus Corporation (OTCPK:OCPNF) Q2 2024 Earnings Conference Call November 9, 2023 1:00 AM ET Company Participants Chikashi Takeda - CFO Stefan Kaufmann - President and CEO Nacho Abia - Executive Officer and Chief Strategy Officer Conference Call Participants Chikashi Takeda...
Olympus Corp. of the Americas to Host Panel Discussion on Lung Cancer Screening Guidelines and Eligibility
Lung Cancer Awareness Month panel will examine who is at risk for lung cancer and what they need to know about the screening process and treatment options CENTER VALLEY, Pa. , Nov. 9, 2023 /PRNewswire/ -- As part of Lung...
Olympus Issues Request to Discontinue Use of UHI-4 Insufflator Unit, Except in Cases Where No Alternative is Available
CENTER VALLEY, Pa. , Oct. 27, 2023 /PRNewswire/ -- Olympus Corporation has announced a field corrective action in the U.S. to address complaints of adverse events from over insufflation during use of the high-flow insufflation unit UHI-4.
Olympus Issues Voluntary Labeling Update for Bronchoscopes Used with Laser Therapy Equipment
CENTER VALLEY, Pa. , July 3, 2023 /PRNewswire/ -- Olympus Corporation has announced a voluntary field corrective action to address complaints of endobronchial combustion occurring when laser-compatible bronchoscopes are used during therapeutic procedures in combination with laser therapy equipment or...
Olympus Corporation (OCPNY) Q3 2023 Earnings Call Transcript
Olympus Corporation (OTCPK:OCPNF) Q3 2023 Earnings Conference Call February 10, 2023 1:00 AM ET Company Participants Yasuo Takeuchi - President and Chief Executive Officer Chikashi Takeda - Chief Financial Officer Nacho Abia - Chief Operating Officer Stefan Kaufmann - Chief...
Olympus Corporation (OCPNY) Q3 2022 Earnings Call Transcript
Olympus Corporation (OTCPK:OCPNY) Q3 2022 Earnings Conference Call November 11, 2022 4:00 AM ET Company Participants Yasuo Takeuchi - President and Chief Executive Officer Chikashi Takeda - Chief Financial Officer Nacho Abia - Chief Operating Officer Stefan Kaufmann - Chief...
Source: https://incomestatements.info
Category: Stock Reports